Hudson Bay Capital Management
CLDX icon

Hudson Bay Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Hudson Bay Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45,000
Closed -$1.14M – 1327
2024
Q4 		$1.14M Buy
+45,000
New +$1.22M ﹤0.01% 726

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's CLDX Position: Q1 2025 in Review

Hudson Bay Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 45,000 shares — an estimated $1.14M sold.

Hudson Bay Capital Management first reported a position in CLDX in Q4 2024 and held it in 1 quarter. The position peaked at $1.14M in Q4 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • Hudson Bay Capital Management reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 45,000 Celldex Therapeutics shares in Q1 2025, an estimated $1.14M.
  • Hudson Bay Capital Management first reported a position in Celldex Therapeutics in Q4 2024 and held it in 1 quarter.
  • Hudson Bay Capital Management's Celldex Therapeutics position peaked at $1.14M in Q4 2024.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Hudson Bay Capital Management's 13F filing for Q1 2025, filed 14 May 2025.